Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 175 participants.

Also called NCT03799627

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 175 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03799627
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03799627. Randomized; no masking; primary purpose treatment. Start 2019-01-31 (actual); primary completion 2020-06-05 (actual). Results posted on 2022-09-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
Acronym
FO2RWARD-2
Condition
Anemia
Condition
Dialysis-dependent Chronic Kidney Disease
Intervention (Drug)
Vadadustat
Intervention (Drug)
Epoetin Alfa
Intervention (Drug)
Vadadustat TIW
Lead sponsor
Akebia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct03799627
Content hash
2155bf6ff27cad25e8c156f8fcffb946f8d24dfc746eed81b1ebd3623378ca99